Efficacy of Concurrent Utilization of Mannitol and Nimodipine in Treating Hypertensive Intracerebral Hemorrhage and Its Effects on Neurological Function.

BACKGROUND

The goal of this study was to retrospectively appraise the efficacy of the combined therapy comprising mannitol and nimodipine for hypertensive intracerebral hemorrhage (HICH) and its impact on neurological function.

METHODS

The study subjects encompassed 100 individuals with HICH who were admitted to the hospital from May 2021 to 2023 and were categorized into a control group and an observation group, with 50 individuals comprising each group. Intravenous mannitol infusion was administered to the control group, while the observation group received nimodipine injection in combination with mannitol, followed by a course of oral nimodipine tablets. Both groups of patients were treated for 3 months. A comparative analysis was performed to assess the clinical efficacy, neurological function, hematoma volume, serum inflammatory cytokine levels, hemodynamic parameters, and incidence of adverse reactions across the 2 groups.

RESULTS

A remarkably higher overall response rate of 92.00% was observed in the treatment group as opposed to 74.00% in the control group, with both groups exhibiting noteworthy reductions in National Institutes of Health Stroke Scale scores post-treatment, and the reduction being more pronounced in the treatment group ( < .05). Post-treatment, both groups exhibited decreases in hematoma volume and edema area, with the reduction in the observation group being notably more significant than in the control group ( < .05). Post-treatment, there was an upsurge in cerebral blood flow and blood flow velocity, coupled with a reduction in peripheral resistance and critical pressure in both groups. The observation group displayed higher blood flow velocity and lower peripheral resistance and critical pressure than the control group ( < .05). No notable distinction was observed in the overall incidence of adverse reactions between the groups ( > .05).

CONCLUSION

The concurrent administration of mannitol and nimodipine in HICH presents substantial advantages, including enhanced clinical efficacy, improved neurological function, decreased hematoma volume, and regulation of hemodynamic parameters. This treatment approach has shown significant efficacy and is worthy of widespread promotion and application in clinical practice.